New pill shows promise for teens with rare brain cancer
NCT ID NCT07286292
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called vorasidenib in 10 teenagers (ages 12 to 17) with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how it affects growth and development, and whether it can shrink or stabilize the tumor. Participants will take the drug for up to 5 years and have regular check-ups including blood tests, MRIs, and growth assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vorasidenib (a targeted drug taken daily as a pill)
What this could lead to
If successful, this could offer a new treatment option for teenagers with certain slow-growing brain tumors, potentially delaying or avoiding the need for more aggressive therapies.
What could go wrong
This is a small, early-phase study with only 10 participants, so results may not apply to all patients. The drug may cause side effects or fail to control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH AN IDH1 OR IDH2 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••